Short answer: the comment period on HHS’s draft peptide policy closed on November 13, 2026, and the policy is still a draft. It lets state-licensed pharmacies, licensed physicians and federal facilities compound six peptides without federal enforcement action, if they meet the policy’s conditions. It is an enforcement policy, not an FDA approval. The six peptides are BPC-157, TB-500, KPV, MOTS-c, epitalon and Semax. Future FDA rulemaking may propose adding some or all of them to the 503A bulks list, and HHS may revisit the policy itself.
Key facts as of November 16, 2026
The primary document is the Federal Register notice. Here are its key facts, dated 2026-11-16.
| Item | What the sources say | Source |
|---|---|---|
| Document | Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances | Federal Register notice |
| Issued by | HHS, Office of the Secretary (not FDA) | Federal Register notice |
| Published | October 30, 2026 (91 FR 68526); filed for public inspection October 28 | Federal Register notice |
| Docket | HHS-OASH-2026-0496 | Federal Register notice |
| Status | Draft, issued as a notice of availability | Federal Register notice |
| Comment deadline | Two weeks after publication, which is November 13, 2026 | Federal Register notice |
| Comment status | Closed, with 289 comments received | Regulations.gov docket page, read November 16, 2026 |
| Peptides covered | BPC-157, TB-500, KPV, MOTS-c, epitalon, Semax | HHS policy Appendix A, as listed by Drug Topics |
| Who it covers | State-licensed 503A pharmacies, federal facilities and licensed physicians | Federal Register notice |
| Legal effect | Not FDA approval; “does not establish any rights for any person and is not binding on HHS or the public” | Federal Register notice |
Did the comment period close?
Yes. The notice accepted written comments until two weeks after publication, which is November 13, 2026. On November 16, the Regulations.gov docket showed comments closed, with 289 received.
In its November 16 article, the Drug Topics article described the comment period as about to close. That description is out of date. The docket showed comments already closed when it was read on November 16. The article also reports that the American Pharmacists Association submitted comments saying evidence is still insufficient for clinicians to counsel patients confidently on long-term safety, drug interactions and outcomes.
Some coverage lags behind. The Muscle & Fitness commentary, published the same day, still describes the notice as open for public comment. For the current status, go by the docket page.
What has to happen before anything changes?
The notice lays out the path. FDA’s future rulemakings “may propose adding some or all of these peptides to the 503A bulks list based on the available evidence.” HHS may revisit the policy, in whole or in part, “if, among other things, a safety signal or product quality issue arises.”
The Alabama medical board’s FAQ, dated November 10, 2026, says the policy has no fixed end date. It applies to each peptide until a final rule includes or excludes that peptide.
Drug Topics reports that FDA scientific reviewers had earlier concluded none of the nominated peptides met the statutory criteria for the bulk drug list, citing limited human clinical trial data and uncertainty about product characterization. It also reports that the American Medical Association adopted policy urging federal health authorities to rescind directives easing compounding limits on unapproved synthetic peptides.
Matt Martin, PharmD, BCSCP, vice president of clinical services at PCCA, stressed to pharmacy leaders in Drug Topics that this is a draft. He advised them to monitor developments. His warning: “What you think is the requirement today may not be the requirement when this policy changes.”
The UCSD Guardian opinion piece quotes Nathan Painter, a clinical professor at UC San Diego’s Skaggs School of Pharmacy and Pharmaceutical Sciences, saying FDA approval typically costs hundreds of millions of dollars and takes 7-10+ years. For how drugmakers move peptides through that process, see why drugmakers pay billions for peptides.
Is this FDA approval?
No. The notice says compounded drugs “are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed,” and that they “also may pose risks to patients.” The Drug Topics article calls the six peptides unapproved. If you want the peptide-by-peptide breakdown, read six unapproved peptides HHS allows.
Has the FDA approved BPC-157?
No. BPC-157 is one of the six peptides in the draft, and the draft is an enforcement position for compounding, not an approval of the peptide. The notice itself makes that distinction.
Who does the draft affect?
The notice names the pharmacies, physicians and facilities it covers. The conditions below come from the Alabama medical board’s FAQ, which summarizes the HHS policy text.
| Who | What the draft means for them |
|---|---|
| State-licensed 503A pharmacies | HHS does not intend to take enforcement action against them for compounding a listed peptide, if they meet the conditions |
| Licensed physicians | The same enforcement position applies to a licensed physician compounding a listed peptide |
| Federal facilities | The same enforcement position applies to a federal facility compounding a listed peptide |
| Patients | The draft’s conditions require a patient-specific prescription |
| Tested athletes | Men’s Fitness says BPC-157, TB-500 and MOTS-c are on the 2026 WADA prohibited list, and a prescription does not make a substance permissible for tested athletes |
The Alabama board’s FAQ lists these conditions:
| Condition | What it requires |
|---|---|
| Ingredient source | An FDA-registered original bulk manufacturer, under CGMP, with a certificate of analysis |
| Ingredient | A single active ingredient |
| Oral forms | Documentation of adequate human oral bioavailability |
| Labeling | Labeled as compounded and not for resale |
| Reporting | Serious adverse events and quality problems reported |
| Device | The only co-packaged device is an FDA 510(k)-cleared syringe |
| Prescription | A patient-specific prescription |
Bring these questions to your pharmacist. Ask your prescriber whether any listed peptide fits your situation.
- Is the pharmacy state-licensed?
- Is the peptide one of the six listed?
- Does the ingredient come from an FDA-registered manufacturer, with a certificate of analysis?
- Is the prescription written for you?
- Who reports serious side effects?
Common mix-ups
| Common mix-up | What the sources say |
|---|---|
| The draft means FDA approved these peptides | No. The notice says compounded drugs “are not FDA-approved.” Enforcement discretion is not approval. |
| It’s an interim policy | The notice calls it a draft. Men’s Fitness’s headline and the policy text say interim, so the draft is best described as a draft interim enforcement policy. |
| FDA issued the notice | HHS’s Office of the Secretary issued it. The outlets name HHS. |
| Comments are still open | Muscle & Fitness describes the notice as open. The docket showed comments closed on November 16. |
| Any online peptide is now allowed | Men’s Fitness says the policy did not make every online product legitimate. Drug Topics reports patients buying these through gray-market “research-use-only” sources. |
| A prescription makes a peptide allowed for athletes | Men’s Fitness says a prescription does not make a substance permissible for tested athletes. |
| The announcement date | UCSD Guardian says HHS announced it Oct. 28. Men’s Fitness says Oct. 30. The Federal Register publication date is Oct. 30. |
What are the risks?
Men’s Fitness explainer reports that FDA has identified potential safety concerns with compounded peptides, including immune reactions and impurities, and that FDA says it lacks important safety information for some substances. The notice itself says compounded drugs “may pose risks to patients.”
The human data is the thin part. Drug Topics reports that FDA reviewers cited limited human clinical trial data. Muscle & Fitness says clinical evidence for sweeping claims in humans is thin. Men’s Fitness quotes Dr. Alex Tatem saying research is uneven and much of it comes from animal work. Tatem advises against treatment for people with active cancer. Men’s Fitness also discloses that Tatem works with Rugiet, a telehealth company that sells peptide treatment. To see what human studies measured, start with peptides human studies (our research library).
Does the FDA regulate compounding pharmacies?
The notice covers compounding under section 503A of the FD&C Act. It is an enforcement position for certain pharmacies and prescribers, not an FDA review of the drugs before they are marketed. State law still applies, and the Alabama board’s FAQ says state boards may restrict these compounds.
Research-use-only peptides are a separate category. Drug Topics says patients are buying these through gray-market “research-use-only” sources online, and the draft’s conditions apply to compounding by licensed pharmacies, physicians and federal facilities.
Key dates
| Date | What happened | Source |
|---|---|---|
| October 28, 2026 | Filed for public inspection (UCSD Guardian says HHS announced the policy this day) | Federal Register notice; UCSD Guardian |
| October 30, 2026 | Published in the Federal Register as 91 FR 68526 | Federal Register notice |
| November 13, 2026 | Comment deadline, two weeks after publication | Federal Register notice |
| November 16, 2026 | Docket shows comments closed, with 289 received | Regulations.gov docket page |
Before you act: what to check next
- Watch the Federal Register for any proposed rule that would add these peptides to the 503A bulks list.
- Ask your prescriber whether a listed peptide fits your situation.
- Ask your pharmacist about state licensing, ingredient source, the certificate of analysis and labeling.
- Check your state board’s rules, since state law still applies.
By HealthDataConsortium.org Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.

